Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 77.93M P/E - EPS this Y 47.10% Ern Qtrly Grth -
Income -76.4M Forward P/E -1.15 EPS next Y 34.70% 50D Avg Chg 1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book 0.92 EPS next 5Y - 52W High Chg -42.00%
Recommedations 2.00 Quick Ratio 2.80 Shares Outstanding 36.91M 52W Low Chg 46.00%
Insider Own 31.90% ROA -49.44% Shares Float 16.43M Beta -0.08
Inst Own 49.46% ROE -107.25% Shares Shorted/Prior 379.49K/57.63K Price 2.84
Gross Margin - Profit Margin - Avg. Volume 15,374 Target Price 5.50
Oper. Margin - Earnings Date Apr 1 Volume 831 Change 1.07%
About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics, Inc. News
04/16/24 Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
04/01/24 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
06:05 AM Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
06:00 AM Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
05:45 AM Gilead bets on Xilio cancer drug as biotech restructures
04:01 PM Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
01/31/24 Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
01/08/24 Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
12/07/23 Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
11/09/23 Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
11/03/23 Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
10/31/23 Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
09/27/23 Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
09/05/23 Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
09/05/23 Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
08/18/23 Q2 2023 Xilio Therapeutics Inc Earnings Call
08/14/23 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
08/03/23 Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
05/25/23 Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
05/09/23 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
XLO Chatroom

User Image Tshanky_ Posted - 2 days ago

$XLO y’all are observant. Just adds fire to the fuel. Big things coming

User Image LabPsycho Posted - 2 days ago

$XLO @ErnieWorthing84 @Tshanky_ Yes, and thanks for posting that....I got the impression listening to the conference that the guy almost implied those events could happen rather quickly - however listening to it again later I dont know where I got that impression from but I was in hurry both times. But I must have had a basis for thinking that.

User Image LabPsycho Posted - 3 days ago

$XLO @Tshanky_ When I listened to their most recent conference call, I got the feeling they let it slip / subtly implied that two more events could happen with GILD this year?

User Image Harley18 Posted - 3 days ago

$XLO

User Image Tshanky_ Posted - 4 days ago

$XLO hoping…I can load the house at .65. Doubt it gets there. I think big second half here

User Image AnalRetort Posted - 4 days ago

@LabPsycho @tradeopen @Scooter0732 Now that my rant is over I still like the science just not as an investor... new reports of tce used in SSC a type of autoimmune condition, replacing car-t cd-19 (lots of reasons car-t is hard). ($Xlo has tce! In dev! ) https://x.com/Majzner_Lab/status/1782616322007785903?t=XgnXaFq4d55tQBAQ8OcQcQ&s=09

User Image Stocks4thought Posted - 4 days ago

$XLO Its happened trade like Biden and then get taken out or deliver great news!

User Image Stocks4thought Posted - 4 days ago

$XLO Not a clue why sell at these levels?

User Image Stocks4thought Posted - 5 days ago

$XLO Trying to shag her for free. NO Cardi B here.

User Image LabPsycho Posted - 6 days ago

$XLO XTX101 Tumor shrinkage

User Image LabPsycho Posted - 1 week ago

$XLO Merck paid well over $600 Million for early stage HARP earlier this year. I think XLO tech > HARP

User Image Harley18 Posted - 1 week ago

$XLO buying dips loading up it’s just a matter of time

User Image LabPsycho Posted - 1 week ago

$XLO Despite my chronic biopessimism, I think XLO, based on trade volume (still quite good on a daily basis considering total outstanding shares), is setting up for a 70% move (hopefully up, LoL)

User Image Aainvest1 Posted - 1 week ago

$XLO can’t stop adding

User Image LabPsycho Posted - 1 week ago

$XLO Let's see...XLO has cash, getting more cash, deals and partnerships with large GILD and ROCHE, working in a hot area (masking antibodies / cytokines - think HARP and HOWL) and some pivotal upcoming milestones - what's not to like?

User Image RallyRaider Posted - 1 week ago

$XLO bot 4000 @ 1.34 holding up very well, keeping trend amid very bad sentiment. should be waay higher given GILD deal and data.

User Image LabPsycho Posted - 1 week ago

$XLO Will masked Antibodies and other biomolecules be this year's hot trend in biotech similar to ADC of last year?

User Image Harley18 Posted - 1 week ago

$XLO bought more

User Image lllIIIII Posted - 1 week ago

$XLO Ok this is enough I buy more

User Image lllIIIII Posted - 1 week ago

$XLO Another dip today please?

User Image Stocks4thought Posted - 2 weeks ago

$RANI other LSD trips $INDP $MRKR $XLO Short Interest (Prior Shares Short) 1,860,000 % From 52-Wk High ($ 5.79) -68.05%

User Image Aainvest1 Posted - 2 weeks ago

$XLO stress free hold

User Image Stocks4thought Posted - 2 weeks ago

$XLO This will be queen soon$

User Image Harley18 Posted - 2 weeks ago

$XLO

User Image lllIIIII Posted - 2 weeks ago

$XLO Was the selloff at 1.53 bagholders finally selling after holding for 6+ months? thank you very much lol

User Image Aainvest1 Posted - 2 weeks ago

$XLO news AH?

User Image Stocks4thought Posted - 2 weeks ago

$XLO Like to see .43

User Image LabPsycho Posted - 2 weeks ago

$XLO Good volume continues and the drift back up. My target is unrealistic and based on subtle body / vocal cues at recent conference call. I think we have not hear the last from GILD this year, and / or lets not forget the possibility that ROCHE could also deepen their collaboration with $XLO. What's this stock price if one or more of these partners potentially come back to the table in the next year? Asking for a friend.

User Image Aainvest1 Posted - 2 weeks ago

$XLO holding till $3+ we getting there soon soon

User Image Scooter0732 Posted - 2 weeks ago

$XLO bullish flag.

Analyst Ratings
Chardan Capital Buy May 30, 23
Chardan Capital Buy May 11, 23
Morgan Stanley Overweight Jan 27, 23
Chardan Capital Buy Dec 21, 22
Raymond James Outperform Nov 10, 22
Morgan Stanley Overweight Aug 10, 22
HC Wainwright & Co. Buy Jan 10, 22
Raymond James Outperform Nov 16, 21
Cowen & Co. Outperform Nov 16, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Atlas Venture Fund XI, L.P. 10% Owner 10% Owner Jan 11 Sell 0.85 4,235 3,600 734,813 01/16/24
Bain Capital Life Sciences Inv... 10% Owner 10% Owner Dec 08 Buy 9.82 42,469 417,046 2,805,413 12/10/21
Flynn James E - - Oct 26 Buy 16 775,000 12,400,000 1,143,972 10/28/21